Armistice Capital, LLC, Director, 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 312,000 shares at $0.88 ($274K) on 2022-01-18, disclosed to the SEC on 2022-01-20.
Open-market purchase of $274k AVTX by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.88 | 206,300 | $182K | 66.2% |
| 2 | $0.88 | 93,700 | $82K | 30.1% |
| 3 | $0.85 | 12,000 | $10K | 3.7% |
| Total | $0.88 avg | 312,000 | $274K | 100% |
| Filing → |
| CERC | BUY | 2021-08-06 | $409K | — | Filing → |
| EYEG | SELL | 2021-08-03 | $830K | — | Filing → |
| CERC | BUY | 2021-05-18 | $392K | — | Filing → |